RNAi News and Research

RSS

New gene-silencing drugs cut cholesterol levels by half in early research

The first in a new class of gene-silencing drugs, known as inclisiran, has been shown to halve cholesterol levels in patients at risk of cardiovascular disease.

21 Mar 2017

Using Spherical Nucleic Acids to Track and Treat Disease

Spherical nucleic acids are structures that are made by taking a nanoparticle template and using chemistry to arrange short strands of DNA or RNA on the surface of those particles. The spherical core of the nanoparticle creates a spherical arrangement of DNA or RNA, similar to tiny little balls of nucleic acids.

From Pittcon 1 Mar 2017

New RNAi treatment safely blocks ocular inflammation in mice

Scientists have developed a new RNA interference therapeutic agent that safely blocked ocular inflammation in mice, potentially making it a new treatment for human uveitis and diabetic retinopathy.

14 Feb 2017

Researchers use CRISPR-based genetic screening to identify three promising HIV treatment targets

Investigators from Whitehead Institute, the Ragon Institute of MGH, MIT and Harvard and the Broad Institute of MIT and Harvard have used CRISPR-Cas9 gene-editing technology to identify three promising new targets for treatment of HIV infection.

20 Dec 2016

UC Riverside scientists identify mechanism that creates immunity to influenza A virus

A team of researchers, co-led by a University of California, Riverside professor, has found a long-sought-after mechanism in human cells that creates immunity to influenza A virus, which causes annual seasonal epidemics and occasional pandemics.

5 Dec 2016

IWGAV establishes strategic recommendations for validating antibody specificity

The International Working Group on Antibody Validation, an independent group of international scientists with diverse research interests in the field of protein biology, today announced the publication of initial strategies developed to address a critical unmet need for antibody specificity, functionality and reproducibility in the September online issue of Nature Methods.

8 Sep 2016

RNA silencing technique developed by spinoff from UM-Madison effective in battling hepatitis B

A method for "silencing" RNA that emerged from a University of Wisconsin-Madison spinoff company is in clinical trials in Europe, Asia and the United States against hepatitis B, an infection that can destroy the liver.

11 Aug 2016

Researchers demonstrate important functional role of lincRNA in immune system

A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.

14 Jul 2016

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis).

6 Jul 2016

First CRISPR/Cas9 screen helps identify human proteins required for Zika virus replication

Scientists at the University of Massachusetts Medical School have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication.

22 Jun 2016

RVFV uses cancer pathway to hijack host cell and cause infection

Viruses can't live without us -- literally. As obligate parasites, viruses need a host cell to survive and grow. Scientists are exploiting this characteristic by developing therapeutics that close off pathways necessary for viral infection, essentially stopping pathogens in their tracks.

17 Jun 2016

High-throughput RNA interference screen identifies potential drug target against henipaviruses

The closely related Hendra and Nipah viruses (referred to jointly as henipaviruses) are deadly cousins of the more common mumps, measles, and respiratory syncytial viruses, all members of the paramyxovirus family. Henipavirus outbreaks are on the rise, but little is known about them, partly because research has to be conducted under extreme level containment conditions.

28 Mar 2016

IMP's Johannes Zuber receives German Cancer Prize 2016

Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research.

24 Feb 2016

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

19 Oct 2015

Study demonstrates effectiveness of new approach to protect humans from infectious disease

There are two common approaches to protecting humans from infectious disease: Targeting pathogens and parasites with medicines like antibiotics, or dealing with the conditions that allow transmission.

8 Sep 2015

RAB35 protein plays role in oncogenic process

A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

4 Sep 2015

IDT webinar explores effective RNAi and antisense oligo methods

Integrated DNA Technologies (IDT) will host an informative webinar, entitled ‘Knockdown of lncRNAs: exploring RNAi and antisense oligo methods’, on Tuesday, August 25, 2015. Kim Lennox, a research scientist at IDT and expert in the suppression of gene expression, will present the webinar at 9 am and 1 pm Central Standard Time.

From Integrated DNA Technologies 19 Aug 2015

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

25 Jul 2015